Table 1.
Patient and treatment characteristics.
| Characteristic | Tumour burden* | P value | ||
|---|---|---|---|---|
| Low | High | |||
| Patient No | 33 | 45 | NA | |
| Age | Median (Range) | 32 (10,73) | 30 (9,68) | 0.4283 |
| Sex | Male, n (%) | 15 (45.45) | 23 (51.11) | 0.6531 |
| Medical history | Ph+, n (%) | 9 (23.27) | 5 (11.11) | 0.0799 |
| ≥ 6 months, n (%) | 26 (78.79) | 28 (62.22) | 0.1415 | |
| Pre-chemotherapy ≥ 3 times, n (%) | 25 (75.76) | 30 (66.67) | 0.4563 | |
| Pre-HSCT, n (%) | 11 (33.33) | 8 (17.78) | 0.1811 | |
| Relapse, n (%) | 28 (84.85) | 29 (64.44) | 0.0695 | |
| Tumour burden evaluation time | Before FC, n (%) | 25 (75.76) | 32 (71.11) | 0.7972 |
| After FC, n (%) | 8 (24.24) | 13 (28.89) | ||
| TP53 mutation | Yes, n (%) | 1 (3.03) | 2 (4.44) | > 0.9999 |
| Cytogenetic risk | Poor, n (%) | 11 (33.33) | 13 (28.89) | 0.8046 |
Ph+ , Philadelphia chromosome-positive; Pre-HSCT, previous haematopoietic stem cell transplantation; TP53, tumor protein P53; FC, fludarabine and cyclophosphamide.
*A high tumor burden was defined as a bone marrow blast level of 5% or more, and a low disease burden was defined as a bone marrow blast level of less than 5%. Minimal residual disease was assessed by multiparameter flow cytometry25, and a negative minimal residual disease status was defined as a bone marrow blast level of less than 0.01%.